Interv Akut Kardiol. 2010;9(3):141-145

Levosimendan - story continued

Jiří Kettner
Klinika kardiologie IKEM, Praha

The contractile dysfunction with peripheral hypoperfusion is main indication for inotropic agents despite the lack of evidence for their

efficacy and safety. A different and unique mechanism of action of levosimendan in comparison to other traditional inotropic drugs

provide a new approach in the management of acute heart failure, particularly in patiens with a history of chronic heart failure and/or

chronically treated with beta-blockers. Advanced possibilities of levosimendan usage are several other clinical settings as myocardial

dysfunction after cardiac surgery or toxic damage in septic shock. Finally, practical recommendations for optimal efficacy and safety

during use of levosimendan are described.

Keywords: levosimendan, inotropic agents, heart failure, cardiac surgery, myocardial dysfunction, septic shock

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kettner J. Levosimendan - story continued. Interv Akut Kardiol. 2010;9(3):141-145.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Califf RM, Adams KF Jr, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54. Go to original source... Go to PubMed...
    2. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138: 78-86. Go to original source... Go to PubMed...
    3. Kellum JA, Decker JM. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001; 29: 1526-1531. Go to original source... Go to PubMed...
    4. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547. Go to original source... Go to PubMed...
    5. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003. Go to original source... Go to PubMed...
    6. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-149. Go to original source... Go to PubMed...
    7. Metra M, Nodari S, D´Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248-1258. Go to original source... Go to PubMed...
    8. Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force frequency and relaxation-frequency relationships. Circulation 2007; 115: 1218-1224. Go to original source... Go to PubMed...
    9. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202. Go to original source... Go to PubMed...
    10. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomised, placebo-controlled, double blind study (RUSSLAN). Eur Heart J 2002; 23: 132-142. Go to original source... Go to PubMed...
    11. Zairis MN, Apostolatos C, Anastassiadis F, et al. Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in low output heart failure (CASINO) study. Eur J Heart Fail 2004; 3(suppl 1): 66. Go to original source...
    12. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure [abstract]. Circulation 2005; 112: 3363.
    13. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891. Go to original source... Go to PubMed...
    14. Cohen-Solal A, Logeart D, Huang B, et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patiens with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343-2348. Go to original source... Go to PubMed...
    15. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34: 2814-2819. Go to original source... Go to PubMed...
    16. Missant C, Rex S, Segers P, Wouters PF. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med 2007; 35: 707-715. Go to original source... Go to PubMed...
    17. Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels 2009; 24: 16-21. Go to original source... Go to PubMed...
    18. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist device. Eur J Cardiothorac Surg 2007; 31: 698-702. Go to original source... Go to PubMed...
    19. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006; 81: 1536-1546. Go to original source... Go to PubMed...
    20. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010; 24: 51-57. Go to original source... Go to PubMed...
    21. Barraud D, Faivre V, Damy T, et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007; 35: 1376-1382. Go to original source... Go to PubMed...
    22. Dubin A, MuriasG, Sottile JP, et al. Effects of levosimendan and dobutamine experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007; 33: 485-494. Go to original source... Go to PubMed...
    23. Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290: F1453-F1462. Go to original source... Go to PubMed...
    24. Morelli A, DeCastro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31: 638-644. Go to original source... Go to PubMed...
    25. Packer M, Carver JR, Rodeheffer RJ, et al. for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475. Go to original source... Go to PubMed...
    26. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231. Go to original source... Go to PubMed...
    27. Hampton JR, van Veldhuisen DJ, Kleber FX, et al, for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-977. Go to original source... Go to PubMed...
    28. Cohn JN, Goldstein SO, Greenberg BH, et al. for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-1816. Go to original source... Go to PubMed...
    29. Nieminen MS, Cleland JGF, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure - The PERSIST study. Eur J Heart Fail 2008; 10: 1246-1254. Go to original source... Go to PubMed...
    30. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.